GSK (NYSE:GSK) Rating Lowered to Hold at Wall Street Zen

Key Points

• GSK has been downgraded from a "buy" to a "hold" rating by Wall Street Zen, reflecting a more cautious outlook from analysts.
• Market analysts have set a consensus target price of $37.38 for GSK, with an average rating of "Hold" across multiple research firms.
• GSK's recent quarterly earnings showed a revenue of $10.06 billion, significantly surpassing analyst estimates of $7.52 billion, indicating strong financial performance despite the downgrade.

GSK (NYSE:GSK - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

A number of other equities analysts have also weighed in on GSK. BNP Paribas initiated coverage on shares of GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price for the company. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Finally, Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $37.38.

GSK Price Performance

GSK opened at $37.95 on Friday. The firm has a market cap of $77.70 billion, a P/E ratio of 19.56, a PEG ratio of 1.56 and a beta of 0.50. The firm has a 50-day moving average of $39.03 and a 200 day moving average of $37.50. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $44.67.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. The firm's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.43 earnings per share. On average, research analysts expect that GSK will post 4.14 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. HHM Wealth Advisors LLC raised its stake in shares of GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares in the last quarter. Costello Asset Management INC purchased a new position in shares of GSK during the first quarter worth approximately $31,000. SOA Wealth Advisors LLC. raised its stake in shares of GSK by 252.1% during the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company's stock worth $32,000 after acquiring an additional 605 shares in the last quarter. Richardson Financial Services Inc. raised its stake in shares of GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares in the last quarter. Finally, Olde Wealth Management LLC purchased a new position in shares of GSK during the first quarter worth approximately $36,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.